Acelyrin, Inc. (SLRN)
| Previous close | 4.8200 |
| Open | 4.8300 |
| Bid | 4.7900 x 100 |
| Ask | 4.8700 x 100 |
| Day's range | 4.7713 - 4.9596 |
| 52-week range | 4.7400 - 29.8800 |
| Volume | |
| Avg. volume | 1,237,375 |
| Market cap | 474.119M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.4300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.17 |
Simply Wall St.Acelyrin Insiders Placed Bullish Bets Worth US$2.65m
Quite a few insiders have dramatically grown their holdings in Acelyrin, Inc. ( NASDAQ:SLRN ) over the past 12 months...
GlobeNewswireACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with high statistical significance in global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis with robust clinical responses also achieved for higher hurdle endpoints Announced differentiated long-term 32-week data from global Phase 2b clinical trial of izokibep in hidradenitis suppurativa – ongoi
GlobeNewswireAvalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq:
